Stockscreener 앱 받기
8.93
3.04%
-0.28
전일 마감가:
$9.21
열려 있는:
$9.37
하루 거래량:
492.85K
Relative Volume:
0.57
시가총액:
$756.15M
수익:
-
순이익/손실:
$-106.81M
주가수익비율:
-2.6965
EPS:
-3.3117
순현금흐름:
$-8.40M
1주 성능:
-3.15%
1개월 성능:
-14.38%
6개월 성능:
-44.08%
1년 성능:
-62.32%
1일 변동 폭
$8.87
$9.49
1주일 범위
$8.385
$9.53
52주 변동 폭
$8.385
$26.70
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
8.93 | 756.15M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Q1 Earnings Forecast for Immunome Issued By Lifesci Capital - Defense World
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $27.17 - Defense World
Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation - Nasdaq
Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Immunome stock hits 52-week low at $8.53 amid market challenges - Investing.com India
Immunome stock hits 52-week low at $8.53 amid market challenges By Investing.com - Investing.com South Africa
Immunome doses first patient in early-stage trial of its experimental cancer treatment -March 10, 2025 at 08:23 am EDT - Marketscreener.com
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Joplin Globe
Immunome Doses First Patient in Phase 1 Cancer Drug Trial - StockTitan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 - BioSpace
Immunome's Latest Talent Investment: 49,000 Share Options Awarded to Key New Hires - StockTitan
Immunome (NASDAQ:IMNM) Sets New 52-Week LowHere's Why - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome stock hits 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
Immunome stock hits 52-week low at $8.97 amid market challenges - Investing.com India
Immunome to Present at Upcoming March Conferences - StockTitan
What Is Going On With Immunome Inc (NASDAQ: IMNM)? - Stocks Register
Immunome CFO receives relocation package, $400K in bonuses - MSN
Where are the Opportunities in (IMNM) - Stock Traders Daily
Three Bridge Wealth Advisors LLC Invests $293,000 in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Trading Down 6.7%Should You Sell? - MarketBeat
Immunome (NASDAQ:IMNM) Trading Up 11.7%Here's What Happened - MarketBeat
Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs - MarketBeat
Immunome (NASDAQ:IMNM) Stock Price Down 6.7% – Here’s What Happened - Defense World
Philadelphia biotech firm backed by more than $130M names new CEO - The Business Journals
Pharma Veteran Behind Immunome's Success Story Named CEO of Rising Biotech Aro - StockTitan
Research Analysts Set Expectations for Immunome Q1 Earnings - Defense World
Checking in on Immunome Inc (IMNM) after recent insiders movement - Knox Daily
After The Stock Fell -1.45% Over The Week, Is Immunome Inc (NASDAQ: IMNM) Still A Buy? - Marketing Sentinel
Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares - MarketBeat
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Rises By 12.2% - MarketBeat
Immunome Inc [IMNM] stock for 1,162,500 USD was acquired by SIEGALL CLAY B - Knox Daily
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - MarketBeat
Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners - Simply Wall St
Strategic Move: Immunome Awards 51,000 Stock Options, Strengthens Executive Team - StockTitan
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
Immunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying Activity - Defense World
Tuesday 2/4 Insider Buying Report: IMNM - Nasdaq
Immunome Inc (IMNM) stock on the rise: An overview - US Post News
Insider Buying: Clay Siegall Acquires 150,000 Shares of Immunome Inc (IMNM) - GuruFocus.com
Immunome (NASDAQ:IMNM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Immunome (NASDAQ:IMNM) Trading Up 7.2%Should You Buy? - MarketBeat
Scharf Investments LLC Takes Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome Closes Public Offering of Shares -January 31, 2025 at 04:13 pm EST - Marketscreener.com
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire
Immunome announces $125 million stock offering - MSN
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):